



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	267460	CAPZEA
ARTG entry for	Medicine Listed	
Sponsor	ATP Science Pty Ltd	
Postal Address	5/63-69 Meakin Road, Meadowbrook, QLD, 4131 Australia	
ARTG Start Date	21/01/2016	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Preparations that contain, as their therapeutically active ingredient, Kunzea ambigua in topical products only, are subject to the following conditions: (i) Must include the label warning (EXTERN) - For external use only; and (ii) Must include the label warning (CHILD) - Keep out of reach of children (or words to that effect).

Products

1 . CAPZEA

Product Type	Single Medicine Product	Effective Date	28/05/2019
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis
Linked indication - Decrease/reduce/relieve mild joint aches and pains
Decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis
Linked indication - Decrease/reduce/relieve mild joint inflammation/swelling
Decrease/reduce/relieve muscle pain/ache/soreness
Decrease/reduce/relieve mild nerve pain/neuralgia

Indication Requirements

Label statement: If symptoms persist, talk to your health professional.
Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis.
Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.
Product presentation must only refer to mild joint symptoms.
Product presentation must only refer to mild nerve pain/neuralgia.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

Public Summary



Australian Government
Department of Health
Therapeutic Goods Administration

Keep out of reach of children (or words to that effect).

For external use only.

Not recommended for use by pregnant and lactating women (or words to that effect).

If symptoms persist consult your healthcare practitioner (or words to that effect).

Avoid contact with eyes (or words to that effect).

Additional Product information

Container information

Type	Material	Life Time	Temperature	Closure	Conditions
Multiple containers	Not recorded	Not recorded	Not recorded	Restricted flow insert	Not recorded

Pack Size/Poison information

Pack Size	Poison Schedule
-----------	-----------------

Components

1 . Formulation 1

Dosage Form Liniment

Route of Administration Topical

Visual Identification

Active Ingredients

Black Pepper Oil	2.3 mg/g
Capsicum annuum	.35 mg/g
Equivalent: capsaicin	332.5 microgram/g
Equivalent: Capsicum annuum	218.75 mg/g
Hypericum perforatum	.23 mg/g
Kunzea ambigua	45 mg/g
Peppermint Oil	45 mg/g
wintergreen oil	50 mg/g
Equivalent: methyl salicylate	49.5 mg/g

Other Ingredients (Excipients)

Grape seed oil

Olive Oil

Sunflower Oil

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary